Lipid-thrombosis interface

British Medical Bulletin

Volumn 50, Issue 4, 1994, Pages 813-832

  Mitropoulos, K A ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; LIPOPROTEIN; LIPOPROTEIN A; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TRIACYLGLYCEROL;

ATHEROMA; BLEEDING TENDENCY; BLOOD CLOTTING; FIBRINOLYSIS; HOMEOSTASIS; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPOLYSIS; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

BLOOD COAGULATION; DIETARY FATS; FACTOR VIII; FIBRINOLYSIS; HUMAN; LIPIDS; LIPOPROTEINS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0028001634     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a072928     Document Type: Article

References (95)

1. Gurr MI. Dietary lipids and coronary heart disease: old evidence, new perspective. Prog Lipid Res 1992; 31: 195–243.
2. Slyper AH. A fresh look at the atherogenic remnant hypothesis. Lancet 1992; 340: 289–291.
3. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533–537.
4. Mitropoulos KA, Esnouf MP, Meade TW. Increased factor VII coagulant activity in the rabbit following diet-induced hypercholesterolaemia. Evidence for increased conversion of VII to αVIIa and higher flux within the coagulation pathway. Atherosclerosis 1987; 63: 43–52.
5. Mitropoulos KA, Walter SJ, Meade TW, Esnouf MP. Increased factor VII reactivity in the rabbit following diet-induced hypercholesterolaemia. Thromb Haemostas 1987; 5: 273.
6. Mitropoulos KA, Esnouf MP. Turnover of factor X and prothrombin in rabbits fed on a standard or cholesterol-supplemented diet. Biochem J 1987; 244: 263–269.
7. Mitropoulos KA, Esnouf MP. The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit Thromb Res 1990; 57: 541–549.
8. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VH levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734–744.
9. Almus FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993;13: 105–111.
10. Lawson JH, Mann KG. Cooperative activation of human factor IX by human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 11317-11327.
11. Miller GJ, Stirling Y, Esnouf MP, et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemostas 1994; 71: 38–48.
12. Conrad J, Bauer KA, Gruber A, et al. Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency Blood 1993;82: 1159–1164.
13. Esmon CT: Molecular events that control the protein C anticoagulant pathway. Thromb Haemostas 1993; 70: 29–35.
14. Negrier C, Berruyer M, Durin A, Philippe N, Dechavanne M. Increased thrombin generation in a child with a combined factor IX and protein C deficiency. Blood 1993, 81: 690–695.
15. Nilsson IM, Bemtorp E, Freiburghaus C: Treatment of patients with factor VIII and IX inhibitors. Thromb Heamostas 1993; 70: 56–59.
16. Ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207–1212.
17. Miller GJ, Wilkes HC, Meade TW, et al. Haemostatic changes that constitute the hypercoagulable state. Lancet 1991; 338: 1079.
18. Miller GJ. Fibrinogen, factor VII, and other haemostatic variables: roles in primary and secondary prevention of coronary heart disease. Cardiovascular Risk Factors 1992; 2: 361–367.
19. Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 1992; 20: 529–531.
20. Esnouf MP. Hyperlipidaemia and its effect on blood coagulation. Cardiovascular Risk Factors 1993; 3: 397–403.
21. Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203–208.
22. Miller GJ, Martin JC, Mitropoulos KA, et al. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163–171.
23. Marckmann P, Sandst om B, Jespersen J. Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis. Atherosclerosis 1993; 101: 225–234.
24. Mitropoulos KA, Miller GJ, Martin JC, Reeves BEA, Cooper J. Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration. Arterioscler Thromb 1994; 14:214–222.
25. Pacy PJH, Mitropoulos KA, Venkatesan S, et al. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase. Atherosclerosis 1993; 103: 231–243.
26. Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis 1992; 94: 119–125.
27. Williams EB, Krishnaswamy S, Mann KG. Zymogen/enzyme discrimination using peptide chloromethylketones. J Biol Chem 1989; 264: 7536–7545.
28. 152 →Glu site-directed mutant of recombinant human blood clotting factor VII. Biochemistry 1990; 29: 3413–3420.
29. Wachtfogel YT, DeLa Cadena RA, Col man RW. Structural biology, cellular interactions and pathophysiology of the contact system. Thromb Res 1993; 72: 1-21.
30. Mitropoulos KA, Esnouf MP. The autoactivation of factor XII in the presence of long-chain saturated fatty acids. A comparison with the potency of sulphatides and dextran sulphate. Thromb Haemostas 1991; 66: 446–452.
31. Mitropoulos KA, Reeves BEA, O’Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coagul Fibrinolysis 1993; 4: 223–234.
32. Mitropoulos KA, Martin JC, Burgess Al, et al. The increased rate of activation of factor XII in late pregnancy can contribute to the increased reactivity of factor VII. Thromb Haemostas 1990; 63: 349–355.
33. Mitropoulos KA, Martin JC, Reeves BEA, Esnouf MP. The activation of the contact phase of coagulation by physiological surfaces in plasma; the effect of large negatively charged liposomal vesicles. Blood 1989; 73: 1525–1533.
34. Broze GJ Jr, Gailani D. The role of factor XI in coagulation. Thromb Haemostas 1993; 70: 72–74.
35. Scott CF, Column RW. Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci USA 1992; 89: 11189–11193.
36. Brunnée T, La Porta C, Reddigarri SR, et al. Activation of factor XI in plasma is dependent on factor XII. Blood 1993; 81:580–586.
37. Wildgoose P, Nemerson Y, Hansen LL, et al. Measurement of basal levels of factor Vila in hemophilia A and B patients. Blood 1992; 80: 25–28.
38. Mitropoulos KA, Reeves BEA, Miller GJ. The activation of factor VII in citraled plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins. Blood Coagul Fibrinolysis 1993; 4: 943–951.
39. Anel A, Richieri GV, Kleinfeld AM. Membrane partition of fatty acids and inhibition of T cell function. Biochemistry 1993; 32: 530–536.
40. Col man RW. Factor XII activation and inhibition in inflammation. Agents Actions Suppl 1993; 42: 125–143.
41. Pixley RA, DeLa Cadena R, Page JD, et al. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992; 40: 897–906.
42. Pixley RA, DeLa Cadena R, Page JD, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61–68.
43. Feingold KR, Staprans I, Memon RA, et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia; low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res 1992; 33: 1765–1776.
44. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1–10.
45. Van der Linden PWG, Hack CE, Eerenberg AJM, Struyvenberg A, Van der Zwan JK. Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood 1993; 82: 1732–1739.
46. Van der Linden PWG, Hack CE, Struyvenberg A, et al. Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock. Blood 1993; 82: 1740–1748.
47. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and - depending interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 2158–2166.
48. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839–2843.
49. Marmur JD, Rossikhina M, Guha A, et al. Tissue factor is rapidly induced in arterial smooth muscle after baloon injury. J Clin Invest 1993; 91: 2253–2259.
50. 2+ mobilization and protein kinase C activation. J Clin Invest 1993; 91: 547– 552.
51. Geelen S, Bhattacharya C, Tuomanen E. Induction of procoagulant activity on human endothelial cells by Streptococcus pneumoniae. Infect Immun 1992; 60: 4179–4183.
52. Kappelmayer J, Bemabei A, Edmunds LH Jr, Edgington TS, Colman RW. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993; 72: 1075–1081.
53. Van Obberghen-Schilling E, Pouységur J. Signaling pathways of thrombin receptor. Thromb Haemostas 1993; 70: 163–167.
54. Welken NA, Soifer SJ, O’Keefe J, et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614–1621.
55. Jaffe EA. The role of blood vessels in hemostasis. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA eds. Hematology, 4th ed. New York: McGraw-Hill 1993; pp1322–1337.
56. Rosenberg RD. Vascular smooth muscle cell proliferation: basic investigations and new therapeutic approaches. Thromb Haemostas 1993; 70: 10–16.
57. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663–665.
58. Moncada S. Biological importance of prostacyclin. Br J of Pharmac 1982: 76: 3–31.
59. 3 on platelet aggregation. Prostaglandins 1979; 18: 453–478.
60. 2 from prostaglandin endoperoxides. Nature 1976; 261: 558–560.
61. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994–2998.
62. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirinlike drugs. Nature (New Biol) 1971; 231: 232–235.
63. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314–319.
64. Dc Nucci G, Gryglewsld RJ, Warner TD, Vane JR. Receptor-mediated release of endotbelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85: 2334–2338.
65. 2 by rat mesangial cells: Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J Clin Invest 1993; 92: 2516–2523.
66. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978; 2: 117–119.
67. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2: 757–761.
68. Fisher M, Levine PH, Weiner B, et al. The effect of vegetarian diets on plasma lipid and platelet levels. Arch Intern Med 1986; 146: 1193–1197.
69. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980; 33: 2657–2661.
70. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the Seven Countries Study. Am J Epidemiol 1986; 124: 903–915.
71. N ordoy A, Goodnight SH. dietary lipids and thrombosis. Relationships to atherosclerosis. Arteriosclerosis 1990; 10: 149–163.
72. Ulbricht TLV, Southgate DAT. Coronary heart disease: seven dietary factors. Lancet 1991; 338: 985–992.
73. Horrobin DF. Omega-6 and omega-3 essential fatty acids in atherosclerosis. Semin Thromb Hemost; 1993; 19: 129–137.
74. Levi M, Hack CE, de Boer JP, et al. Contact system dependent fibrinolytic activity in vivo: observations in healthy subjects and factor XII deficient patients. Agents Actions Suppl. 1992; 38: 292–298.
75. Loskutoff DJ, Sawdey M, Keeton M, Schoneiderman J. Regulation of PAI-1 gene expression in vivo. Thromb Haemostas 1993; 70: 135–137.
76. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator- inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165–169.
77. Lambers JWJ, Cammenga M, K onig BW, et al. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492–17496.
78. Erickson LA, Fici GJ, Lund JE, et al. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74–76.
79. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 3: 528–532.
80. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief Report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frameshift mutation. N Engl J Med 1992; 327: 1729–1733.
81. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998–7002.
82. Tremoli E. Triglycerides and fibrinolytic activity. Cardiovascular Risk Factors 1993; 3: 333–335.
83. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemostas 1993; 70: 138–143.
84. Thompson SG, Van De Loo JCW. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8–17.
85. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067–1073.
86. Mussoni L, Maderaa F, Camera M, et al. Atherogenic lipoproteins and release of plasminogen activator inhibitor 1 (PAI-1) by endothelial cells. Fibrinolysis 1990; (suppl 2): 79–81.
87. Latron Y, Chautan M, Anfosso F, et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor 1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821–1829.
88. Tremoli E, Camera M, Maderma P, et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscer Thromb 1993; 13: 338–346.
89. Chautan M, Latron Y, Anfosso F, et al. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor 1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res 1993; 34: 101–110.
90. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein (a) accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992; 90: 52–60.
91. Schreiner PJ, Morrisett JD, Schanett AR, et al. Lipoprotein (a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993; 13: 826–833.
92. Nomura S, Yamamura T, Yamamoto A, et al. The association between lipoprotein(a) and severity of coronary and cerebrovascular atherosclerosis, especially in non-hypercholesterolemic subjects. Cardiovasc Risk Factors 1993; 3: 336–343.
93. Rouy D, Laplaud PM, Saboureau M, Anglès-Cano E. Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study. Arterioscler Thromb 1992; 12: 146–154.
94. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432–437.
95. Malekzadeh S, Dressier FA, Hoeg JM, Brewer JB Jr, Roberts WC. Left atrial endocardial lipid deposits and absent to minimal arterial lipid deposits in familial hyperchylomicronemia. Am J Cardiol 1991; 67: 1431–1434.